Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > What is the reason

<< Previous

Bullboard Posts

Next >>

Post by amendison Jul 13, 2021 10:48pm

394 Views

Post# 33540658

What is the reason

What is the reason Ifonprodi drop out 3 phase. what FDA said its not worth to go? 30 years go ONE coo said FDA not treat Canadian companies not treat fairly. NO death find in and doctors said drug is good. Why FDA comment release to share holders.

<< Previous

Bullboard Posts

Next >>

First Helium advances winter drilling program with Leduc Anomaly test well